Derivatives of Omega-3 HUFA as Biomarkers of Traumatic Brain Injury
Status:
Recruiting
Trial end date:
2023-12-01
Target enrollment:
Participant gender:
Summary
This is a Phase 2 clinical trial designed to obtain data on relationships between potentially
therapeutic doses of n-3 HUFA (highly unsaturated fatty acids) and their bioactive molecular
derivatives, synaptamide, 17-hydroxy-DHA, and D-series resolvins, on clinical outcomes after
TBI.
Phase:
Phase 2
Details
Lead Sponsor:
University of Pennsylvania
Collaborator:
National Institute on Alcohol Abuse and Alcoholism (NIAAA)